menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Imfinzi Shows EFS Benefit In Early Gastric, GEJ Cancers

    BUSINESSWIRE

    AstraZeneca gets CDSCO approval to import, sell cancer medicine

    ECONOMICTIMES

    AIM doses first subject in Phase 2 study of Ampligen and Imfinzi

    GLOBENEWSWIRE

    IMFINZI Perioperative Regimen Boosts Survival In Bladder Cancer

    BUSINESSWIRE

    AIM ImmunoTech Releases Virtual Investor “What This Means” Segment

    GLOBENEWSWIRE

    Erasmus Safety Committee Approves Ph 2 Study for Pancreatic Cancer

    GLOBENEWSWIRE

    FDA approves Imfinzi for limited-stage small cell lung cancer

    REUTERS

    AstraZeneca`s Biologic Imfinzi Receives Suppl Approval in US

    FDA

    Akeso Enrolls 1st Patient in Ivonescimab Biliary Tract Cancer Trial

    PR NEWSWIRE

    Govt asks manufacturers to cut price of 3 anti-cancer drugs

    ECONOMICTIMES

    AstraZeneca Pharma India to launch Tremelimumab

    INDIANPHARMAPOST

    AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study

    GLOBENEWSWIRE

    AstraZeneca`s Imfinzi extends life in bladder cancer type

    FIERCE PHARMA

    Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer

    BUSINESSWIRE

    IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial

    BUSINESSWIRE

    Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

    PR NEWSWIRE

    AstraZeneca Advances Cancer Care Standards at WCLC and ESMO 2024

    BUSINESSWIRE

    Imfinzi Approved In U.S. For Resectable Non-Small Cell Lung Cancer

    BUSINESSWIRE

    AstraZeneca`s Imfinzi gets FDA priority review for type of lung cancer

    REUTERS

    Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis

    FIERCE PHARMA

    AstraZeneca`s Biologic Imfinzi (Durvalumab) Receives Suppl Approvals in US

    FDA

    FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi

    BIOSPACE

    AZ`s Imfinzi fails in late-stage trial to treat certain lung cancers

    REUTERS

    IMFINZI shows results in Phase III trial for muscle-invasive bladder cancer.

    BUSINESSWIRE

    AZ Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

    REUTERS

    Astrazeneca Uk Biologic Durvalumab Receives Suppl Approval in US

    FDA

    IMFINZI Reduces Death Risk By 27% In Limited-Stage SCLC

    BUSINESSWIRE

    As Bristol Myers reveals trial failure, AstraZeneca`s Imfinzi stays king in stage 3 lung cancer

    FIERCE PHARMA

    AIM ImmunoTech: Ampligen+Imfinzi Combo Tolerated in Pancreatic Cancer Study

    GLOBENEWSWIRE

    AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

    BIOPHARMADIVE

    AstraZeneca UK Imfinzi (Durvalumab) Receives Approval in the U.S.

    FDA

    IMFINZI® + Chemo Doubled 3-Yr OS In Biliary Tract Cancer TOPAZ-1

    BUSINESSWIRE

    AstraZeneca`s Imfinzi improves survival in late-stage lung cancer trial

    REUTERS

    IMFINZI Significantly Improved Overall Survival in ADRIATIC Phase III Trial

    BUSINESSWIRE

    AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need

    BIOSPACE

    AIM ImmunoTech Announces First Subject Dosed for Phase 1b/2 Evaluating Ampligen

    GLOBENEWSWIRE

    AIM ImmunoTech Announces Enrollment in the Phase 1b/2 Evaluating Ampligen

    GLOBENEWSWIRE

    AstraZeneca`s Imfinzi combo extends PFS in liver cancer

    ENDPTS

    AIM ImmunoTech Announces Open Enrollment for Ph 1b/2 Study Evaluating Ampligen

    GLOBENEWSWIRE

    AstraZeneca`s Biologic Imfinzi (durvalumab) Receives Approval in the U.S.

    FDA

    BioCity announces first patient dosed with anti-TIM-3 mAb BC3402 with IMFINZI

    PR NEWSWIRE

    Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

    BUSINESSWIRE

    Imfinzi plus chemotherapy approved in China as first immunotherapy regimen

    PRESS RELEASE

    AstraZeneca`s Imfinzi plus chemoradiotherapy fail main goal of late stage trial

    REUTERS

    IMFINZI & bevacizumab met endpoint for progression-free survival in liver cancer

    BUSINESSWIRE

    Theriva Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01

    GLOBENEWSWIRE

    Datopotamab deruxtecan plus IMFINZI Shows Durable tumor responses in BEGONIA Ph Ib/II trial

    BUSINESSWIRE

    IMFINZI plus LYNPARZA reduced the risk of death by 45% in endometrial cancer

    BUSINESSWIRE

    IMFINZI plus chemotherapy doubled pathologic complete response rate in GEJ

    BUSINESSWIRE

    Datopotamab Deruxtecan Plus Durvalumab Showed Promising Activity in the NSCLC

    BUSINESSWIRE

    Perioperative Durvalumab Plus SOC Shows Promising EFS Results Muscle-Invasive UC

    ONCLIVE

    IMFINZI plus IMJUDO® demonstrated sustained overall survival benefit in ALC

    BUSINESSWIRE

    First Patient Dosed in Ph2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

    BUSINESSWIRE

    LYNPARZA & IMFINZI combination reduced risk of death in advanced ovarian cancer

    BUSINESSWIRE

    IMFINZI plus chemotherapy improved response in MATTERHORN PIII trial

    BUSINESSWIRE

    AstraZeneca reports positive results from endometrial cancer therapy trial

    CLINICAL TRIALS ARENA

    Imfinzi plus Lynparza and Imfinzi alone both improved progression-free survival in advanced endometrial cancer

    PRESS RELEASE

    Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression

    ENDPTS

    BMS accuses AZ of Opdivo patent infringement in new lawsuit

    FIERCE PHARMA

    AZ`s Imfinzi-Lynparza will face tough FDA scrutiny: analyst

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.